Rituximab (anti-CD20 monoclonal antibody) administration in a young patient with resistant B-prolymphocytic leukemia.

Abstract

Following the administration of the human anti-CD20 monoclonal antibody IDEC-C2B8 (rituximab), a 31-year-old woman with B-prolymphocytic leukemia, who had been resistant to CHOP, fludarabine, pentostatin and 2-CdA, achieved complete remission. Rituximab was administered intravenously once a week for 4 weeks. The patient only had mild but tolerable side effects during the first cycle of therapy. She remains in complete remission 8 months following the discontinuation of treatment.

• Authors: G Vartholomatos, S Tsiara, L Christou, A Panteli, P Kaiafas, K L Bourantas
• Journal: Acta haematologica (Acta Haematol) Vol. 102 Issue 2 Pg. 94-8 ( 1999) ISSN: 0001-5792 [Print] Switzerland
• PMID: 10529513 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Murine-Derived
• Antineoplastic Agents
• Rituximab

Topics

• Adult
• Antibodies, Monoclonal (therapeutic use)
• Antibodies, Monoclonal, Murine-Derived
• Antineoplastic Agents (therapeutic use)
• Drug Resistance, Multiple
• Drug Resistance, Neoplasm
• Female
• Humans
• Leukemia, B-Cell (drug therapy)
• Leukemia, Promyelocytic, Acute (drug therapy)
• Rituximab